United States CAR-T Cell Therapy Market Growth & Key Players Analysis | Major Players 2025 - Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company

"The Global CAR-T cell therapy market reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/car-t-cell-therapy-market?sp

United States: Recent CAR-T Cell Therapy Developments

✅ In September 2025, Kite Pharma (Gilead) launched a next-generation CAR-T therapy targeting multiple myeloma in California.The therapy features dual-antigen targeting to improve response rates and reduce relapse risk.It expands treatment options for relapsed/refractory patients.

✅ In August 2025, Novartis invested $60 million to expand its CAR-T manufacturing facility in New Jersey.The expansion focuses on scaling production and reducing manufacturing time.Commercial rollout is expected by Q1 2026.

✅ In July 2025, Legend Biotech introduced a new CAR-T therapy candidate for B-cell malignancies in New York.The therapy incorporates a proprietary construct to enhance persistence and efficacy in clinical trials.It is entering Phase 3 testing.

✅ In June 2025, Bluebird Bio completed clinical trials of its optimized CAR-T platform for pediatric leukemia in Massachusetts.The results demonstrated higher remission rates and improved safety profiles.It supports accelerated regulatory submission.

Japan: Recent CAR-T Cell Therapy Developments

✅ In September 2025, Fujifilm Cellular Dynamics launched a CAR-T research platform in Tokyo.The platform integrates cell engineering, AI-driven analysis, and manufacturing optimization to support development of novel CAR-T therapies.

✅ In August 2025, Takeda Pharmaceuticals invested in CAR-T production and clinical research facilities in Osaka.The initiative focuses on leukemia and lymphoma therapies.Commercial availability is targeted for 2026.

✅ In July 2025, Kite Pharma Japan introduced a new CAR-T therapy trial for multiple myeloma patients in Kyoto.The therapy leverages dual-target CAR constructs to improve efficacy and reduce relapse risk.Pilot trials are ongoing in leading cancer centers.

✅ In June 2025, Cellular Dynamics Japan completed validation of an automated CAR-T manufacturing system in Fukuoka.The platform enhances scalability, quality control, and safety for clinical applications.It will support nationwide CAR-T trials.

CAR-T Cell Therapy Market: Drivers

The CAR-T cell therapy market is experiencing significant growth as healthcare providers and biopharmaceutical companies increasingly adopt innovative immunotherapies to treat hematologic cancers and other malignancies. Rising adoption is driven by the therapy's ability to engineer patients' T-cells to specifically target and destroy cancer cells, offering personalized and highly effective treatment options. Additionally, increasing prevalence of leukemia, lymphoma, and multiple myeloma, combined with growing awareness of advanced cancer treatments, is fueling market demand. Expansion of clinical trials, research initiatives, and investment in cell and gene therapy infrastructure further supports market growth. The focus on precision medicine and patient-specific immunotherapies is also contributing to rising adoption.

Technological advancements are significantly enhancing CAR-T cell therapy. Innovations in gene editing, viral and non-viral vectors, and cell manufacturing techniques improve efficacy, safety, and scalability. Development of next-generation CAR-T constructs, including dual-targeting and armored CAR-T cells, expands therapeutic potential and reduces relapse rates. Advances in automated cell processing, cryopreservation, and quality control systems streamline production and ensure consistent therapy quality. Integration with AI, bioinformatics, and predictive modeling supports patient selection, dosing optimization, and outcome monitoring. With ongoing innovation and growing adoption in oncology, the CAR-T cell therapy market is poised for substantial growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/car-t-cell-therapy-market?sp

CAR-T Cell Therapy Market: Major Players

Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Autolus Therapeutics, Pfizer Inc., BioNTech SE., Merck KGaA, Allogene Therapeutics, Atara Biotherapeutics, Inc. and among others.

Segment Covered in the CAR-T Cell Therapy Market:

➥ By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy

➥ By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta

➥ By Target Antigen: CD19, BCMA (B-cell Maturation Antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others

➥ By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others

Research Process:

Both primary and secondary data sources have been used in the CAR-T Cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the CAR-T Cell Therapy Market Research Industry:

âž  Who leads the CAR-T Cell Therapy industry and what's their competitive positioning regarding capacity, performance, and profitability?
âž  What growth opportunities and market challenges do CAR-T Cell Therapy market vendors face?
âž  Which segments show the highest growth potential and market share distribution?
âž  What factors are driving or limiting CAR-T Cell Therapy market growth?
âž  What are the dominant sales and distribution strategies in the CAR-T Cell Therapy industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=car-t-cell-therapy-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.